vs
Side-by-side financial comparison of F5, Inc. (FFIV) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
PERRIGO Co plc is the larger business by last-quarter revenue ($1.1B vs $811.7M, roughly 1.4× F5, Inc.). F5, Inc. runs the higher net margin — 18.2% vs -127.8%, a 146.0% gap on every dollar of revenue. On growth, F5, Inc. posted the faster year-over-year revenue change (11.0% vs -2.5%). Over the past eight quarters, F5, Inc.'s revenue compounded faster (8.0% CAGR vs 1.3%).
F5, Inc. is an American technology company specializing in application security, multi-cloud management, online fraud prevention, application delivery networking (ADN), application availability and performance, and network security, access, and authorization.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
FFIV vs PRGO — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $811.7M | $1.1B |
| Net Profit | $148.0M | $-1.4B |
| Gross Margin | 81.4% | 32.6% |
| Operating Margin | 22.1% | -116.0% |
| Net Margin | 18.2% | -127.8% |
| Revenue YoY | 11.0% | -2.5% |
| Net Profit YoY | 1.5% | -3093.9% |
| EPS (diluted) | $2.58 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $811.7M | — | ||
| Q4 25 | $822.5M | $1.1B | ||
| Q3 25 | $810.1M | $1.0B | ||
| Q2 25 | $780.4M | $1.1B | ||
| Q1 25 | $731.1M | $1.0B | ||
| Q4 24 | $766.5M | $1.1B | ||
| Q3 24 | $746.7M | $1.1B | ||
| Q2 24 | $695.5M | $1.1B |
| Q1 26 | $148.0M | — | ||
| Q4 25 | $180.1M | $-1.4B | ||
| Q3 25 | $190.5M | $7.5M | ||
| Q2 25 | $189.9M | $-8.4M | ||
| Q1 25 | $145.5M | $-6.4M | ||
| Q4 24 | $166.4M | $-44.4M | ||
| Q3 24 | $165.3M | $-21.0M | ||
| Q2 24 | $144.1M | $-108.4M |
| Q1 26 | 81.4% | — | ||
| Q4 25 | 81.5% | 32.6% | ||
| Q3 25 | 82.2% | 36.1% | ||
| Q2 25 | 81.0% | 34.4% | ||
| Q1 25 | 80.7% | 37.6% | ||
| Q4 24 | 81.7% | 33.9% | ||
| Q3 24 | 80.8% | 37.2% | ||
| Q2 24 | 80.4% | 37.0% |
| Q1 26 | 22.1% | — | ||
| Q4 25 | 26.0% | -116.0% | ||
| Q3 25 | 25.4% | 7.0% | ||
| Q2 25 | 25.2% | 4.3% | ||
| Q1 25 | 21.7% | 4.5% | ||
| Q4 24 | 26.8% | 10.0% | ||
| Q3 24 | 25.6% | 7.4% | ||
| Q2 24 | 23.4% | -2.5% |
| Q1 26 | 18.2% | — | ||
| Q4 25 | 21.9% | -127.8% | ||
| Q3 25 | 23.5% | 0.7% | ||
| Q2 25 | 24.3% | -0.8% | ||
| Q1 25 | 19.9% | -0.6% | ||
| Q4 24 | 21.7% | -3.9% | ||
| Q3 24 | 22.1% | -1.9% | ||
| Q2 24 | 20.7% | -10.2% |
| Q1 26 | $2.58 | — | ||
| Q4 25 | $3.10 | $-10.23 | ||
| Q3 25 | $3.25 | $0.05 | ||
| Q2 25 | $3.25 | $-0.06 | ||
| Q1 25 | $2.48 | $-0.05 | ||
| Q4 24 | $2.82 | $-0.32 | ||
| Q3 24 | $2.79 | $-0.15 | ||
| Q2 24 | $2.44 | $-0.79 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.6B | $2.9B |
| Total Assets | $6.5B | $8.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.3B | $432.1M | ||
| Q2 25 | $1.4B | $454.2M | ||
| Q1 25 | $1.3B | $409.9M | ||
| Q4 24 | $1.2B | $558.8M | ||
| Q3 24 | $1.1B | $1.5B | ||
| Q2 24 | $935.6M | $542.8M |
| Q1 26 | $3.6B | — | ||
| Q4 25 | $3.5B | $2.9B | ||
| Q3 25 | $3.6B | $4.4B | ||
| Q2 25 | $3.5B | $4.5B | ||
| Q1 25 | $3.3B | $4.4B | ||
| Q4 24 | $3.2B | $4.3B | ||
| Q3 24 | $3.1B | $4.6B | ||
| Q2 24 | $3.0B | $4.5B |
| Q1 26 | $6.5B | — | ||
| Q4 25 | $6.3B | $8.5B | ||
| Q3 25 | $6.3B | $10.1B | ||
| Q2 25 | $6.1B | $10.1B | ||
| Q1 25 | $5.9B | $9.8B | ||
| Q4 24 | $5.9B | $9.6B | ||
| Q3 24 | $5.6B | $11.2B | ||
| Q2 24 | $5.4B | $10.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $525.1M | $175.4M |
| Free Cash FlowOCF − Capex | — | $148.6M |
| FCF MarginFCF / Revenue | — | 13.4% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | 3.55× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $525.1M | — | ||
| Q4 25 | $159.2M | $175.4M | ||
| Q3 25 | $208.1M | $51.7M | ||
| Q2 25 | $282.2M | $75.9M | ||
| Q1 25 | $256.6M | $-64.5M | ||
| Q4 24 | $202.8M | $312.6M | ||
| Q3 24 | $246.5M | $42.2M | ||
| Q2 24 | $159.0M | $9.5M |
| Q1 26 | — | — | ||
| Q4 25 | $149.5M | $148.6M | ||
| Q3 25 | $191.9M | $29.8M | ||
| Q2 25 | $273.7M | $56.7M | ||
| Q1 25 | $246.1M | $-90.0M | ||
| Q4 24 | $194.7M | $274.9M | ||
| Q3 24 | $240.4M | $15.1M | ||
| Q2 24 | $153.1M | $-18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 18.2% | 13.4% | ||
| Q3 25 | 23.7% | 2.9% | ||
| Q2 25 | 35.1% | 5.4% | ||
| Q1 25 | 33.7% | -8.6% | ||
| Q4 24 | 25.4% | 24.2% | ||
| Q3 24 | 32.2% | 1.4% | ||
| Q2 24 | 22.0% | -1.8% |
| Q1 26 | — | — | ||
| Q4 25 | 1.2% | 2.4% | ||
| Q3 25 | 2.0% | 2.1% | ||
| Q2 25 | 1.1% | 1.8% | ||
| Q1 25 | 1.4% | 2.4% | ||
| Q4 24 | 1.1% | 3.3% | ||
| Q3 24 | 0.8% | 2.5% | ||
| Q2 24 | 0.8% | 2.7% |
| Q1 26 | 3.55× | — | ||
| Q4 25 | 0.88× | — | ||
| Q3 25 | 1.09× | 6.89× | ||
| Q2 25 | 1.49× | — | ||
| Q1 25 | 1.76× | — | ||
| Q4 24 | 1.22× | — | ||
| Q3 24 | 1.49× | — | ||
| Q2 24 | 1.10× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FFIV
Segment breakdown not available.
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
